Takeaways: Zasocitinib’s Phase 3 win over deucravacitinib suggests it could become a best-in-class oral TYK2 option for moderate-to-severe plaque psoriasis if regulators...
Biosimilars were introduced with the promise of expanding access to biologic therapies while reducing healthcare costs. As more blockbuster biologics lose exclusivity, biosimilars are becoming an incr...
For decades, oncology innovation has focused primarily on developing more effective treatments for advanced disease. Today, however, the industry is beginning to shift toward a new frontier: detecting...
Precision medicine is often defined by breakthrough therapies and targeted treatments, but behind many of these advances lies a less visible yet increasingly essential component: companion diagnostics...
The COVID-19 pandemic fundamentally transformed the global vaccine industry, accelerating scientific innovation, manufacturing investment, and public awareness at an unprecedented pace. Technologies t...
Rare diseases were once considered commercially unattractive due to their limited patient populations and high development costs. Today, however, they have become one of the fastest growing areas of i...
Sustainability in the pharmaceutical industry is evolving beyond environmental, social, and governance reporting into a broader strategic priority. What was once viewed primarily as a corporate respon...
The Obesity Drug Gold Rush: Healthcare Breakthrough or Market Frenzy? The global pharmaceutical industry is witnessing an unprecedented surge in demand for obesity therapies, transforming what was onc...
The healthcare and biopharma industries are facing a growing talent crisis that threatens to slow innovation and place additional strain on already burdened systems. Within Canadian Health, workforce ...
For all the scientific advances in drug development, clinical trials remain one of the most inefficient and fragile components of the system. Patient recruitment is slow and costly, retention rates ar...
